Mitochondrial reprogramming induced by CaMKIIδ mediates hypertrophy decompensation.

RATIONALE Sustained activation of Gαq transgenic (Gq) signaling during pressure overload causes cardiac hypertrophy that ultimately progresses to dilated cardiomyopathy. The molecular events that drive hypertrophy decompensation are incompletely understood. Ca(2+)/calmodulin-dependent protein kinase II δ (CaMKIIδ) is activated downstream of Gq, and overexpression of Gq and CaMKIIδ recapitulates hypertrophy decompensation. OBJECTIVE To determine whether CaMKIIδ contributes to hypertrophy decompensation provoked by Gq. METHODS AND RESULTS Compared with Gq mice, compound Gq/CaMKIIδ knockout mice developed a similar degree of cardiac hypertrophy but exhibited significantly improved left ventricular function, less cardiac fibrosis and cardiomyocyte apoptosis, and fewer ventricular arrhythmias. Markers of oxidative stress were elevated in mitochondria from Gq versus wild-type mice and respiratory rates were lower; these changes in mitochondrial function were restored by CaMKIIδ deletion. Gq-mediated increases in mitochondrial oxidative stress, compromised membrane potential, and cell death were recapitulated in neonatal rat ventricular myocytes infected with constitutively active Gq and attenuated by CaMKII inhibition. Deep RNA sequencing revealed altered expression of 41 mitochondrial genes in Gq hearts, with normalization of ≈40% of these genes by CaMKIIδ deletion. Uncoupling protein 3 was markedly downregulated in Gq or by Gq expression in neonatal rat ventricular myocytes and reversed by CaMKIIδ deletion or inhibition, as was peroxisome proliferator-activated receptor α. The protective effects of CaMKIIδ inhibition on reactive oxygen species generation and cell death were abrogated by knock down of uncoupling protein 3. Conversely, restoration of uncoupling protein 3 expression attenuated reactive oxygen species generation and cell death induced by CaMKIIδ. Our in vivo studies further demonstrated that pressure overload induced decreases in peroxisome proliferator-activated receptor α and uncoupling protein 3, increases in mitochondrial protein oxidation, and hypertrophy decompensation, which were attenuated by CaMKIIδ deletion. CONCLUSIONS Mitochondrial gene reprogramming induced by CaMKIIδ emerges as an important mechanism contributing to mitotoxicity in decompensating hypertrophy.

[1]  Inna Dubchak,et al.  Whole-Genome rVISTA: a tool to determine enrichment of transcription factor binding sites in gene promoters from transcriptomic data , 2013, Bioinform..

[2]  C. Indolfi,et al.  Genetic Deletion of Uncoupling Protein 3 Exaggerates Apoptotic Cell Death in the Ischemic Heart Leading to Heart Failure , 2013, Journal of the American Heart Association.

[3]  T. Horvath,et al.  Mitochondria in Cardiovascular Physiology and Disease Role of uncoupling protein 3 in ischemia-reperfusion injury , arrhythmias , and preconditioning , 2013 .

[4]  C. Chen,et al.  Protective Effects of Acyl-coA Thioesterase 1 on Diabetic Heart via PPARα/PGC1α Signaling , 2012, PloS one.

[5]  E. Abel,et al.  UCP3 Regulates Cardiac Efficiency and Mitochondrial Coupling in High Fat–Fed Mice but Not in Leptin-Deficient Mice , 2012, Diabetes.

[6]  Xiaoxue Zhang,et al.  Parkin Protein Deficiency Exacerbates Cardiac Injury and Reduces Survival following Myocardial Infarction*♦ , 2012, The Journal of Biological Chemistry.

[7]  Mark E. Anderson,et al.  CaMKII determines mitochondrial stress responses in heart , 2012, Nature.

[8]  Mark E. Anderson,et al.  Calmodulin-dependent protein kinase II: linking heart failure and arrhythmias. , 2012, Circulation research.

[9]  X. Wehrens,et al.  Human Stanniocalcin-1 Suppresses Angiotensin II-Induced Superoxide Generation in Cardiomyocytes through UCP3-Mediated Anti-Oxidant Pathway , 2012, PloS one.

[10]  T. Saikawa,et al.  Activation of CaMKII as a key regulator of reactive oxygen species production in diabetic rat heart. , 2012, Journal of molecular and cellular cardiology.

[11]  S. Akira,et al.  Mitochondrial DNA That Escapes from Autophagy Causes Inflammation and Heart Failure , 2012, Nature.

[12]  Michael A. Burke,et al.  Targeting myocardial substrate metabolism in heart failure: potential for new therapies , 2012, European journal of heart failure.

[13]  Mark E. Anderson,et al.  Oxidation of CaMKII determines the cardiotoxic effects of aldosterone , 2011, Nature Medicine.

[14]  Donald M Bers,et al.  CaMKII in myocardial hypertrophy and heart failure. , 2011, Journal of molecular and cellular cardiology.

[15]  J. Brown,et al.  Crossing signals: relationships between β-adrenergic stimulation and CaMKII activation. , 2011, Heart rhythm.

[16]  Niels Voigt,et al.  Oxidized CaMKII causes cardiac sinus node dysfunction in mice. , 2011, The Journal of clinical investigation.

[17]  M. Brand,et al.  High Throughput Microplate Respiratory Measurements Using Minimal Quantities Of Isolated Mitochondria , 2011, PloS one.

[18]  R. deKemp,et al.  Hexokinase II acts through UCP3 to suppress mitochondrial reactive oxygen species production and maintain aerobic respiration. , 2011, The Biochemical journal.

[19]  Mark E. Anderson,et al.  CaMKII in the cardiovascular system: sensing redox states. , 2011, Physiological reviews.

[20]  Ajit S. Divakaruni,et al.  The regulation and physiology of mitochondrial proton leak. , 2011, Physiology.

[21]  C. Zechner,et al.  Uncoupling protein downregulation in doxorubicin-induced heart failure improves mitochondrial coupling but increases reactive oxygen species generation , 2011, Cancer Chemotherapy and Pharmacology.

[22]  S. Collins,et al.  Glutathionylation Acts as a Control Switch for Uncoupling Proteins UCP2 and UCP3* , 2011, The Journal of Biological Chemistry.

[23]  T. Prolla,et al.  Mitochondrial Oxidative Stress Mediates Angiotensin II–Induced Cardiac Hypertrophy and G&agr;q Overexpression–Induced Heart Failure , 2011, Circulation research.

[24]  M. Rogawski,et al.  Seizure Protection by Intrapulmonary Delivery of Propofol Hemisuccinate , 2011, Journal of Pharmacology and Experimental Therapeutics.

[25]  J. Farber,et al.  Cyclophilin D controls mitochondrial pore-dependent Ca(2+) exchange, metabolic flexibility, and propensity for heart failure in mice. , 2010, The Journal of clinical investigation.

[26]  A. Newton,et al.  PHLPP-1 Negatively Regulates Akt Activity and Survival in the Heart , 2010, Circulation research.

[27]  Ajit S. Divakaruni,et al.  The regulation and turnover of mitochondrial uncoupling proteins. , 2010, Biochimica et biophysica acta.

[28]  Derek J Van Booven,et al.  Deep mRNA Sequencing for In Vivo Functional Analysis of Cardiac Transcriptional Regulators: Application to G&agr;q , 2010, Circulation research.

[29]  R. Chen,et al.  The effects of a PPARalpha agonist on myocardial damage in obese diabetic mice with heart failure. , 2010, International heart journal.

[30]  N. Dalton,et al.  Phospholamban Ablation Rescues Sarcoplasmic Reticulum Ca2+ Handling but Exacerbates Cardiac Dysfunction in CaMKII&dgr;C Transgenic Mice , 2010, Circulation research.

[31]  M. MacCoss,et al.  Overexpression of Catalase Targeted to Mitochondria Attenuates Murine Cardiac Aging , 2009, Circulation.

[32]  Tong Zhang,et al.  Requirement for Ca2+/calmodulin-dependent kinase II in the transition from pressure overload-induced cardiac hypertrophy to heart failure in mice. , 2009, The Journal of clinical investigation.

[33]  Hugo A. Katus,et al.  The δ isoform of CaM kinase II is required for pathological cardiac hypertrophy and remodeling after pressure overload , 2009, Proceedings of the National Academy of Sciences.

[34]  M. Emond,et al.  Reduction of age-associated pathology in old mice by overexpression of catalase in mitochondria. , 2008, The journals of gerontology. Series A, Biological sciences and medical sciences.

[35]  Mark E. Anderson,et al.  A Dynamic Pathway for Calcium-Independent Activation of CaMKII by Methionine Oxidation , 2008, Cell.

[36]  G. Dorn,et al.  Inhibition of Apoptosis-Regulated Signaling Kinase-1 and Prevention of Congestive Heart Failure by Estrogen , 2007, Circulation.

[37]  G. Dorn The Fuzzy Logic of Physiological Cardiac Hypertrophy , 2007, Hypertension.

[38]  T. Kato,et al.  Attenuation of cardiac dysfunction by a PPAR-alpha agonist is associated with down-regulation of redox-regulated transcription factors. , 2006, Journal of molecular and cellular cardiology.

[39]  Guy Salama,et al.  Calmodulin kinase II inhibition protects against structural heart disease , 2005, Nature Medicine.

[40]  E. Olson,et al.  Cardiac hypertrophy: the good, the bad, and the ugly. , 2003, Annual review of physiology.

[41]  Tong Zhang,et al.  The &dgr;C Isoform of CaMKII Is Activated in Cardiac Hypertrophy and Induces Dilated Cardiomyopathy and Heart Failure , 2003, Circulation research.

[42]  K. Chien,et al.  Absence of pressure overload induced myocardial hypertrophy after conditional inactivation of Gαq/Gα11 in cardiomyocytes , 2001, Nature Medicine.

[43]  G. Dorn,et al.  Transgenic Gαq overexpression induces cardiac contractile failure in mice , 1997 .

[44]  K. Chien,et al.  The alpha 1A-adrenergic receptor subtype mediates biochemical, molecular, and morphologic features of cultured myocardial cell hypertrophy. , 1993, The Journal of biological chemistry.

[45]  W. Kannel,et al.  Precursors of sudden coronary death. Factors related to the incidence of sudden death. , 1975, Circulation.

[46]  M. Gheorghiade,et al.  Enhancing the metabolic substrate: PPAR-alpha agonists in heart failure , 2010, Heart Failure Reviews.

[47]  W. Koch,et al.  Genetic Alterations That Inhibit In Vivo Pressure-Overload Hypertrophy Prevent Cardiac Dysfunction Despite Increased Wall Stress , 2002, Circulation.

[48]  K. Chien,et al.  Absence of pressure overload induced myocardial hypertrophy after conditional inactivation of Galphaq/Galpha11 in cardiomyocytes. , 2001, Nature medicine.

[49]  G. Dorn,et al.  Transgenic Galphaq overexpression induces cardiac contractile failure in mice. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[50]  D E Manyari,et al.  Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. , 1990, The New England journal of medicine.